Livzon Pharmaceutical Group Inc. (01513) Announces Monthly Return for February 2026

Bulletin Express03-02

Livzon Pharmaceutical Group Inc. submitted its monthly return for the period ended 28 February 2026 on 2 March 2026. The announcement indicates no changes in total authorised share capital, with the aggregate authorised amount remaining at 887.91 million shares. Of this total, 299.81 million shares are H shares listed on The Stock Exchange of Hong Kong Limited, while 588.10 million shares are A shares listed on the Shenzhen Stock Exchange.

According to the filing, no new share issuances, repurchases, or treasury shares were recorded during the month. The company confirms compliance with the current 5% public float requirement for its H shares, and no changes took place in share structure or treasury share arrangements. No outstanding share options, warrants, or convertible securities were reported.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130626679?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130626679","market":"us","top_or_hot":-1,"title":"Livzon Pharmaceutical Group Inc. (01513) Announces Monthly Return for February 2026","media":"Bulletin Express","content":"<p>Livzon Pharmaceutical Group Inc. submitted its monthly return for the period ended 28 February 2026 on 2 March 2026. The announcement indicates no changes in total authorised share capital, with the aggregate authorised amount remaining at 887.91 million shares. Of this total, 299.81 million shares are H shares listed on The Stock Exchange of Hong Kong Limited, while 588.10 million shares are A shares listed on the Shenzhen Stock Exchange.</p>\n<p>According to the filing, no new share issuances, repurchases, or treasury shares were recorded during the month. The company confirms compliance with the current 5% public float requirement for its H shares, and no changes took place in share structure or treasury share arrangements. No outstanding share options, warrants, or convertible securities were reported.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Livzon Pharmaceutical Group Inc. (01513) Announces Monthly Return for February 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivzon Pharmaceutical Group Inc. (01513) Announces Monthly Return for February 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-02 17:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Livzon Pharmaceutical Group Inc. submitted its monthly return for the period ended 28 February 2026 on 2 March 2026. The announcement indicates no changes in total authorised share capital, with the aggregate authorised amount remaining at 887.91 million shares. Of this total, 299.81 million shares are H shares listed on The Stock Exchange of Hong Kong Limited, while 588.10 million shares are A shares listed on the Shenzhen Stock Exchange.</p>\n<p>According to the filing, no new share issuances, repurchases, or treasury shares were recorded during the month. The company confirms compliance with the current 5% public float requirement for its H shares, and no changes took place in share structure or treasury share arrangements. No outstanding share options, warrants, or convertible securities were reported.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"丽珠医药","start_time":0,"source_url":"","article_id":"1130626679","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130626679","pubTimestamp":1772444064,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Livzon Pharmaceutical Group Inc. submitted its monthly return for the period ended 28 February 2026 on 2 March 2026. The announcement indicates no changes in total authorised share capital, with the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药"},"translate_title":"丽珠医药集团股份有限公司(01513)公布2026年2月月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"Livzon Pharmaceutical Group Inc. submitted its monthly return for the period ended 28 February 2026 on 2 March 2026. The announcement indicates no changes in total authorised share capital, with the aggregate authorised amount remaining at 887.91 million shares. Of this total, 299.81 million shares are H shares listed on The Stock Exchange of Hong Kong Limited, while 588.10 million shares are A shares listed on the Shenzhen Stock Exchange.\nAccording to the filing, no new share issuances, repurchases, or treasury shares were recorded during the month. The company confirms compliance with the current 5% public float requirement for its H shares, and no changes took place in share structure or treasury share arrangements. No outstanding share options, warrants, or convertible securities were reported.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130626679","isCrawlerRequest":true}